| |
| |
|
| Insider
Information: |
Conterno Enrique A |
| Relationship: |
Chief Executive Office... |
| City: |
Indianapolis |
| State: |
IN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
507,684 |
|
|
Indirect Shares
|
32,959 |
|
|
| Direct
Value |
$113,428,565 |
|
|
|
Indirect Value
|
$4,415,678 |
|
|
| Total
Shares |
540,643 |
|
|
| Total
Value |
$117,844,243 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
7
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
2
|
7
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
-7.0
|
| Percentage
Gain/Loss : |
 -5.7%
|
-569.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
SVP&Pres, LillyDiab & ... |
2019-02-15 |
132,962 |
2019-02-15 |
5,159 |
Premium* |
|
|
Fibrogen Inc |
FGEN |
Chief Executive Office... |
2023-07-07 |
374,722 |
2023-07-07 |
27,800 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2022-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
179,400 |
312,104 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2023-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
85,300 |
380,783 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
82,000 |
137,273 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2023-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
60,349 |
416,460 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2020-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
60,000 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2013-01-25 |
4 |
A |
$53.21 |
$1,756,835 |
D/D |
33,017 |
60,029 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2014-01-28 |
4 |
A |
$54.23 |
$1,748,809 |
D/D |
32,248 |
89,425 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2013-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,768 |
91,797 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2023-03-10 |
4 |
S |
$20.20 |
$638,013 |
D/D |
(31,589) |
384,868 |
0 |
% |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2015-01-28 |
4 |
A |
$70.97 |
$2,131,726 |
D/D |
30,037 |
104,400 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2019-02-04 |
4/A |
A |
$120.17 |
$3,206,376 |
D/D |
26,682 |
157,962 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2019-02-04 |
4 |
A |
$120.17 |
$3,206,256 |
D/D |
26,681 |
157,961 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2015-12-09 |
4 |
S |
$83.88 |
$2,097,000 |
D/D |
(25,000) |
88,131 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2017-05-04 |
4 |
S |
$82.76 |
$2,069,000 |
D/D |
(25,000) |
114,217 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-05-31 |
4 |
AS |
$85.00 |
$2,125,000 |
D/D |
(25,000) |
124,534 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2019-02-15 |
4 |
AS |
$121.00 |
$3,025,000 |
D/D |
(25,000) |
132,962 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2023-03-08 |
4 |
S |
$21.16 |
$521,958 |
D/D |
(24,672) |
356,111 |
0 |
% |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,326 |
147,980 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2017-01-27 |
4 |
A |
$75.38 |
$1,523,505 |
D/D |
20,211 |
133,783 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
158,468 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2016-01-26 |
4 |
A |
$81.96 |
$1,635,348 |
D/D |
19,953 |
108,084 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2020-06-11 |
4 |
B |
$35.28 |
$698,599 |
I/I |
19,800 |
27,800 |
2.66 |
% |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2011-01-25 |
4 |
A |
$34.73 |
$682,688 |
D/D |
19,657 |
44,895 |
0 |
- |
|
| FGEN |
Fibrogen Inc |
Chief Executive Officer |
• • – |
2023-03-10 |
4/A |
S |
$20.20 |
$393,625 |
D/D |
(19,489) |
384,868 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Sr. VP & Pres., Diabetes BU |
• – – |
2010-01-26 |
4 |
A |
$36.16 |
$662,994 |
D/D |
18,335 |
27,727 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
